Notice of Amendment of RFA-AR-19-028 "HEAL Initiative: Back Pain Consortium (BACPAC) Research Program Technology Research Sites (UH2/UH3 Clinical Trial Optional)

Notice Number: NOT-AR-19-036

Key Dates
Release Date : February 20, 2019

Related Announcements
RFA-AR-19-028

Issued by
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Purpose

The purpose of this Notice is to amend RFA-AR-19-028 "HEAL Initiative: Back Pain Consortium (BACPAC) Research Program Technology Research Sites (UH2/UH3 Clinical Trial Optional).” The following sections have been modified:

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

Technology Research Sites
Research Objectives

Currently reads:

The following are non-responsive to this RFA and will not be reviewed:

  • Biomarker discovery or validation
  • Development of new drugs
  • Research involving the use of animal models is not excluded; however, any proposed animal model(s) must be highly relevant to human conditions and the demonstrated application to humans must be included in the specific aims of the proposed project(s).
  • Technology development focused on metastatic bone disease or chronic low back pain due to acute or chronic infection or acute trauma.
Modified to read:

The following are non-responsive to this RFA and will not be reviewed:

  • Development of new drugs.
  • Research involving the use of animal models is not excluded; however, any proposed animal model(s) must be highly relevant to human conditions and the demonstrated application to humans must be included in the specific aims of the proposed project(s).
  • Technology development focused on metastatic bone disease or chronic low back pain due to acute or chronic infection or acute trauma.

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Xincheng Zheng, M.D., Ph.D.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Telephone: 301-594-4953
Email: BACPAC-NIH@mail.nih.gov